Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kenneth Paris

Allergy & Immunology New Orleans, LA Medical Doctor

NPI 1629183157 CMS profile 346338

200 Henry Clay Ave, New Orleans, LA 70118

Open in the dashboard

General payments

$150,253

233 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$115,798 paid to institutions, not to them · program years 2024–2025

Through program year 2025, Kenneth Paris of New Orleans, LA is reported in the CMS Open Payments database as having received $150,253 across 233 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $115,798 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 95th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,255 25
2024 General $37,504 45
2023 General $43,260 57
2022 General $21,702 41
2021 General $12,314 11
2020 General $18,152 11
2019 General $12,066 43

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kenneth Paris
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Kenneth Paris were reported at $5,255. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Kenneth Paris Allergy & Immunology median Middle half National median
2019 $12,066 $594 $163–$1,512 $163
2020 $18,152 $426 $106–$1,233 $114
2021 $12,314 $638 $157–$1,708 $132
2022 $21,702 $790 $205–$1,961 $149
2023 $43,260 $852 $220–$2,147 $160
2024 $37,504 $865 $203–$2,267 $164
2025 $5,255 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Takeda Pharmaceuticals U.S.A., Inc. $113,240 110 payments
  2. BioCryst US Sales Co., LLC $8,048 11 payments
  3. Shire North American Group Inc $7,180 14 payments
  4. Grifols USA, LLC $6,184 9 payments
  5. GlaxoSmithKline, LLC. $6,049 10 payments
  6. BioCryst Pharmaceuticals, Inc. $3,649 9 payments
  7. CSL Behring $3,097 22 payments
  8. Pfizer Inc. $925 1 payment
  9. Genzyme Corporation $471 13 payments
  10. Amgen Inc. $424 12 payments
  11. Other $986 22 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $82,599 26 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $45,016 8 payments
  3. Travel and Lodging $12,898 43 payments
  4. Food and Beverage $6,714 154 payments
  5. Honoraria $3,025 2 payments
Products named General payments · program years 2019–2025
  1. CUVITRU $46,312 45 payments
  2. HYQVIA $19,927 26 payments
  3. NUCALA $5,908 8 payments
  4. Xembify $5,740 8 payments
  5. Hizentra $2,988 19 payments
  6. Privigen $2,523 2 payments
  7. TAKHZYRO $1,991 7 payments
  8. Gamunex-C $771 4 payments
  9. DUPIXENT $517 15 payments
  10. Orladeyo $365 10 payments
  11. Other $1,123 33 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

233 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record